Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- Biotech Association Asks MHLW to Include Drugs for Intractable Diseases and Orphan Drugs in Early Approval System
February 18, 2013
- JMA President Yokokura Opposes TPP Agreement, Expressing Concerns over Intervention in NHI Pricing
February 15, 2013
- PPTA President Airs Concern over Japanese Govt Intervention in Price Setting of Blood Products
February 13, 2013
- RAD-AR Council to Set Guidelines for Information Provisioning on Ethical Drugs
February 12, 2013
- JMA Exec. Mikami Wants a Hold on Info Disclosures Based on Transparency Guidelines
February 8, 2013
- Permanent Introduction of Premium for New Drug Development One of PhRMA’s “Priorities in 2013”: Japan Chair
February 5, 2013
- JMA Submits Petition Calling on MHLW to include 7 Vaccines in Public Vaccination Program
February 1, 2013
- Wholesale Industry FTC Prohibits Drink Donations at Academic Confabs, Keeps Pace with Drug Makers
January 31, 2013
- Number of CMRs on the Increase, Reaching 3,365: JCSOA Survey
January 30, 2013
- 1st MR Qualification Exam under New Education and Training System Attains 81.3% Pass Rate
January 29, 2013
- Wholesale Industry FTC Curbs Returns of Drugs to Be Discarded
January 29, 2013
- JMA Establishes Council to Discuss Transparency Guidelines, Will JPMA Be Able to Put Doctors’ Concerns to Rest?
January 29, 2013
- Drug Damage Watchdog Calls for Online OTC Drug Sales Ban in Principle
January 28, 2013
- JGA President Sawai Promises to Ensure Quality and Secure Stable Supply of Generics
January 24, 2013
- JPMA Bolstering ICH Activities to Propose New Topics from Industry
January 18, 2013
- JPMA Approves New “Code of Practice”
January 18, 2013
- JPA Expresses Deep Regrets over Court Ruling on Online Sale of OTC Drugs
January 16, 2013
- JMA Vice Pres. Nakagawa Urges Pharmacies to Rigidly Check Medical Exam History of Epadel OTC Buyers
January 15, 2013
- JMA Sets Up “Council on Medical COI” Out of Concerns Over Transparency GL
January 11, 2013
- JPWA Chief Bessho Calls for Clearer Rule for Sales Tax on Ethical Drugs
January 10, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…